These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33498915)

  • 1. Bayesian Approaches for Confirmatory Trials in Rare Diseases: Opportunities and Challenges.
    Ursino M; Stallard N
    Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33498915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian Strategies in Rare Diseases.
    Garczarek U; Muehlemann N; Richard F; Yajnik P; Russek-Cohen E
    Ther Innov Regul Sci; 2023 May; 57(3):445-452. PubMed ID: 36566312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.
    Kidwell KM; Roychoudhury S; Wendelberger B; Scott J; Moroz T; Yin S; Majumder M; Zhong J; Huml RA; Miller V
    Orphanet J Rare Dis; 2022 May; 17(1):186. PubMed ID: 35526036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma.
    Hirakawa A; Nishikawa T; Yonemori K; Shibata T; Nakamura K; Ando M; Ueda T; Ozaki T; Tamura K; Kawai A; Fujiwara Y
    Ther Innov Regul Sci; 2018 May; 52(3):334-338. PubMed ID: 29714533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.
    Brown AR; Gajewski BJ; Aaronson LS; Mudaranthakam DP; Hunt SL; Berry SM; Quintana M; Pasnoor M; Dimachkie MM; Jawdat O; Herbelin L; Barohn RJ
    Trials; 2016 Aug; 17(1):428. PubMed ID: 27577191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using phase II data for the analysis of phase III studies: An application in rare diseases.
    Wandel S; Neuenschwander B; Röver C; Friede T
    Clin Trials; 2017 Jun; 14(3):277-285. PubMed ID: 28387537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases.
    Sebastien B
    J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):495-499. PubMed ID: 37148459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.
    Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD
    Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol.
    Stunnenberg BC; Woertman W; Raaphorst J; Statland JM; Griggs RC; Timmermans J; Saris CG; Schouwenberg BJ; Groenewoud HM; Stegeman DF; van Engelen BG; Drost G; van der Wilt GJ
    BMC Neurol; 2015 Mar; 15():43. PubMed ID: 25880166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A framework for applying unfamiliar trial designs in studies of rare diseases.
    Gupta S; Faughnan ME; Tomlinson GA; Bayoumi AM
    J Clin Epidemiol; 2011 Oct; 64(10):1085-94. PubMed ID: 21530171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research and drug development activities in rare diseases: differences between Japan and Europe regarding influence of prevalence.
    Mizoguchi H; Yamanaka T; Kano S
    Drug Discov Today; 2016 Oct; 21(10):1681-1689. PubMed ID: 27371505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and analysis features used in small population and rare disease trials: A targeted review.
    Partington G; Cro S; Mason A; Phillips R; Cornelius V
    J Clin Epidemiol; 2022 Apr; 144():93-101. PubMed ID: 34910979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian dose selection design for a binary outcome using restricted response adaptive randomization.
    Meinzer C; Martin R; Suarez JI
    Trials; 2017 Sep; 18(1):420. PubMed ID: 28886745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative designs for clinical trials in rare diseases.
    Abrahamyan L; Feldman BM; Tomlinson G; Faughnan ME; Johnson SR; Diamond IR; Gupta S
    Am J Med Genet C Semin Med Genet; 2016 Dec; 172(4):313-331. PubMed ID: 27862920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive design of confirmatory trials: Advances and challenges.
    Lai TL; Lavori PW; Tsang KW
    Contemp Clin Trials; 2015 Nov; 45(Pt A):93-102. PubMed ID: 26079372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial.
    Cellamare M; Milstein M; Ventz S; Baudin E; Trippa L; Mitnick CD
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):8-12. PubMed ID: 28240566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian methods for design and analysis of safety trials.
    Price KL; Xia HA; Lakshminarayanan M; Madigan D; Manner D; Scott J; Stamey JD; Thompson L
    Pharm Stat; 2014; 13(1):13-24. PubMed ID: 23897858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian adaptive trials for rare cardiovascular conditions.
    Shohoudi A; Stephens DA; Khairy P
    Future Cardiol; 2018 Mar; 14(2):143-150. PubMed ID: 29405070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian model with application for adaptive platform trials having temporal changes.
    Wang C; Lin M; Rosner GL; Soon G
    Biometrics; 2023 Jun; 79(2):1446-1458. PubMed ID: 35476298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.